Not So Different: Steven C. Hill, PhD, Discusses Rebates and Specialty Drug Spending

November 8, 2020

In an interview with The Center for Biosimilars®, Steven C. Hill, PhD, a senior economist with the Agency for Healthcare Research and Quality, discusses a recent study he co-authored on specialty drug spending.

In a recent study, investigators focused on net spending on specialty medicine after manufacturer rebates. What they found was a sharp rise in net specialty drug spending, but they also noted that use of rebates was rapidly increasing, too. This was true for both public and private payers. We discussed these findings with lead study author Steven C. Hill, PhD, a senior economist with the Division of Research and Modeling, Center for Financing, Access and Cost Trends, at the Agency for Healthcare Research and Quality in Rockville, MD.

To learn more about this study, click here.